Edition:
United States

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

7.77CAD
15 Dec 2017
Change (% chg)

$0.18 (+2.37%)
Prev Close
$7.59
Open
$7.59
Day's High
$7.92
Day's Low
$7.58
Volume
934,331
Avg. Vol
198,933
52-wk High
$11.00
52-wk Low
$7.51

Latest Key Developments (Source: Significant Developments)

KNIGHT THERAPEUTICS REPORTS Q3 EARNINGS PER SHARE $0.03
Thursday, 9 Nov 2017 06:00am EST 

Nov 9 (Reuters) - Knight Therapeutics Inc :KNIGHT REPORTS THIRD QUARTER 2017 RESULTS.QTRLY ‍REVENUE $1.9 MILLION, A DECREASE OF 2 PERCENT​.QTRLY EARNINGS PER SHARE $0.03‍​.‍ALL CURRENCIES ARE CANADIAN​.  Full Article

Knight Therapeutics reports qtrly earnings per share $0.03‍​
Thursday, 9 Nov 2017 06:00am EST 

Nov 9 (Reuters) - Knight Therapeutics Inc ::Knight reports third quarter 2017 results.Qtrly earnings per share $0.03.Q3 earnings per share view C$0.03 -- Thomson Reuters I/B/E/S‍​.Qtrly ‍revenues were $1.9 million, a decrease of 2 percent versus same period in prior year​.All currencies are Canadian‍​.  Full Article

Knight Therapeutics announces increase in ownership of Crescita Therapeutics
Tuesday, 10 Oct 2017 08:00am EDT 

Oct 10 (Reuters) - Knight Therapeutics Inc :Knight Therapeutics - ‍pursuant to early warning requirements of national instrument 62-103, co announced increase in ownership of Crescita Therapeutics.Knight Therapeutics Inc - ‍now owns aggregate of 2.08 million common shares of crescita representing about 14.9 pct of outstanding common shares of Crescita​.  Full Article

Knight Therapeutics amended its secured loan agreement with Crescita Therapeutics
Monday, 14 Aug 2017 08:35am EDT 

Aug 14 (Reuters) - Crescita Therapeutics Inc :Knight Therapeutics Inc - Amended its secured loan agreement with Crescita Therapeutics Inc.Knight Therapeutics - To receive early repayment of $2.5 million of loan, agreed to release letter of credit for general security interest over all of Crescita's assets.  Full Article

Crescita Therapeutics announces amended loan agreement with Knight Therapeutics
Monday, 14 Aug 2017 08:30am EDT 

Aug 14 (Reuters) - Crescita Therapeutics Inc :Crescita Therapeutics announces amended loan agreement with Knight Therapeutics.Crescita Therapeutics Inc - ‍announced it has entered into an amended loan agreement with Knight Therapeutics Inc​.Crescita Therapeutics Inc - ‍under terms of amended loan agreement, Crescita will immediately repay $2.5 million of loan​.Crescita Therapeutics Inc - Knight has agreed to release letter of credit in exchange for a general security interest over all of Crescita's assets​.Crescita Therapeutics - has access to additional $6.0 million of cash that was previously restricted under terms of letter of credit - to fund operations​.Crescita Therapeutics - ‍loan continues to bear interest at 9% per annum and matures on January 22, 2022​.Entered into an amended loan agreement with knight therapeutics inc.Crescita agreed to make additional repayments such that principal amount of loan is reduced to $2.5 million by December 31, 2018​.  Full Article

Knight Therapeutics qtrly earnings per share $‍0.003​
Thursday, 10 Aug 2017 06:02am EDT 

Aug 10 (Reuters) - Knight Therapeutics Inc ::Knight reports second quarter 2017 results.Qtrly earnings per share $‍0.003​.  Full Article

Knight Therapeutics reports second quarter 2017 results
Thursday, 10 Aug 2017 06:01am EDT 

Aug 10 (Reuters) - Knight Therapeutics Inc :Knight reports second quarter 2017 results.Qtrly ‍shr $0.003​.All figures in C$.  Full Article

Knight Therapeutics ‍issues additional secured loan of $10 mln to Synergy CHC
Wednesday, 9 Aug 2017 05:00pm EDT 

Aug 10 (Reuters) - Knight Therapeutics Inc -:Knight Therapeutics Inc - ‍issued an additional secured loan of us$10 million to Synergy CHC Corp​.Knight Therapeutics Inc - ‍additional secured loan of us$10 million bears interest at 10.5% per annum and matures on august 9, 2020​.  Full Article

Knight therapeutics Q1 EPS $0.04
Thursday, 11 May 2017 06:00am EDT 

May 11 (Reuters) - Knight Therapeutics Inc ::Knight Therapeutics Inc qtrly revenues of $1.8 million, an increase of $682,000 over same period last year.Knight reports first quarter 2017 results.Qtrly diluted earnings per share $0.04.Received full repayment of balance of secured loans to Apicore Inc. and Pro Bono Bio Plc in the quarter.  Full Article

Knight Therapeutics rewarded for doing Pro Bono
Tuesday, 28 Mar 2017 05:00pm EDT 

Knight Therapeutics Inc - :Assigned its secured loan issued to Pro Bono Bio Plc and has received full repayment of balance.  Full Article